The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) is of global concern: the virus has caused severe respiratory illness, with 111 confirmed cases and 52 deaths 1 at the time of this article's publication. Therapeutic interventions have not been evaluated in vivo; thus, patient management relies exclusively on supportive care, which, given the high case-fatality rate, is not highly effective. The rhesus macaque is the only known model organism for MERS-CoV infection, developing an acute localized to widespread pneumonia with transient clinical disease 2,3 that recapitulates mild to moderate human MERSCoV cases 4, 5 . The combination of interferon-α2b and ribavirin was effective in reducing MERS-CoV replication in vitro 6 ; therefore, we initiated this treatment 8 h after inoculation of rhesus macaques. In contrast to untreated, infected macaques, treated animals did not develop breathing abnormalities and showed no or very mild radiographic evidence of pneumonia. Moreover, treated animals showed lower levels of systemic (serum) and local (lung) proinflammatory markers, in addition to fewer viral genome copies, distinct gene expression and less severe histopathological changes in the lungs. Taken together, these data suggest that treatment of MERS-CoV infected rhesus macaques with IFN-α2b and ribavirin reduces virus replication, moderates the host response and improves clinical outcome. As these two drugs are already used in combination in the clinic for other infections, IFN-α2b and ribavirin should be considered for the management of MERS-CoV cases.
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MERS-CoV is the first lineage-C betacoronavirus known to infect humans 7 . Similar to SARS (severe acute respiratory syndrome) coronavirus infection, MERS-CoV infection can result in an acute respiratory distress syndrome with multiorgan dysfunction 8 . The rapid identification of therapeutics for MERS-CoV is a high priority as there is currently no specific therapy or vaccine. A meta-analysis of data from the SARS outbreak in 2003 9 found that the benefit of different treatment strategies [10] [11] [12] [13] [14] [15] [16] [17] [18] was inconclusive at best 9 . We recently demonstrated in vitro that the antiviral effect of interferon-a2b (IFN-a2b) against MERS-CoV is augmented by the concomitant use of ribavirin, and when we combined the treatments, the effective concentrations were such that they could be used in the clinic 6 . Here we evaluate the effectiveness in vivo of combination IFN-a2b and ribavirin treatment, in an attempt to identify a therapeutic approach that can be immediately implemented in the clinic for MERS-CoV cases.
Two groups of three rhesus macaques were infected with 7 × 10 6 , the TCID 50 (50% tissue culture infectious dose), of MERS-CoV (hCoV-EMC/2012, a clinical isolate 8 ), as previously described 2 . We initiated treatment 8 h after infection, with subcutaneous delivery of 5 mega international units (MIU)/kg of IFN-a2b and an intravenous loading dose of ribavirin (30 mg per kg body weight). We subsequently treated the rhesus macaques with ribavirin intramuscularly (10 mg per kg body weight) every 8 h and IFN-a2b (5 MIU/kg) subcutaneously every 16 h until 72 h after infection, when all animals were euthanized (Fig. 1a) at the peak of clinical signs and viral loads in this model 2, 3 .
Infection with MERS-CoV in the absence of treatment led to similar clinical signs as previously reported, including increased respiration rates, abdominal breathing and piloerection 2, 3 (Fig. 1b and Supplementary Table 1 ). The animals' observed breathing difficulties were supported by evidence of decreased oxygen saturation in untreated animals (2-5% decrease from baseline) (Fig. 1c) . We observed significantly increased white blood cell counts in untreated animals 1 d after infection, but they returned to normal levels on subsequent days (Fig. 1d) . We attributed the increase in white blood cells mainly to a significant increase in neutrophils (Fig. 1e) . In contrast, treated animals did not show evidence of increased respiration, piloerection or decreased oxygen saturation levels, nor did they show significant changes in hematology (Fig. 1d,e) . To monitor signs of pneumonia, we X-rayed the animals daily. Radiographs from treated animals remained normal 1 d after infection and showed, at most, light in treated animals, all respiratory tract tissues collected at necropsy were positive for MERS-CoV by qRT-PCR (Fig. 3b) . Viral RNA was also absent from the tonsils, spleen and kidney of treated animals, but it was present in these tissues in two of three untreated animals. In all of the tissues analyzed, with the exception of left middle lobe lung specimens, the viral loads were lower in specimens from treated animals as compared to untreated animals ( Fig. 3b) . When we combined the values from all lung specimens, the mean viral load in treated animals was 0.81 log lower than in untreated animals (P = 0.0428, unpaired t-test, one tail), demonstrating a statistically significant reduction in virus replication throughout the lung (Fig. 3b, inset) .
All animals developed some degree of pulmonary pathology with mild to marked multifocal bronchointerstitial pneumonia, predominantly centered on the terminal bronchioles (Fig. 3c,d) . However, untreated rhesus macaques 4 and 5 showed moderate to marked lesions with abundant alveolar edema, fibrin with formation of hyaline membranes and low to moderate numbers of macrophages (Fig. 3d) , a lesion severity not observed in the treated animals ( Fig. 3c and Supplementary Table 3 ). Only untreated animals showed significant scoring for perivascular infiltrates within and adjacent to affected areas of the lung (Fig. 3d) (P < 0.001, Mann-Whitney). We observed higher numbers of neutrophils in lungs of untreated animals compared to treated ones (9.3% compared to 6.1%, respectively) (Fig. 3e) .
infiltration in a single lobe 2 or 3 d after infection in one or two of three animals, respectively (Supplementary Table 2 ). In contrast, untreated animals showed evidence of increasing amounts of interstitial infiltration between 1 and 3 d after infection, ranging from localized (single lobe) to diffuse severe pulmonary interstitial infiltration throughout the lungs ( Fig. 2 and Supplementary Table 2) .
Upon necropsy, gross pathology revealed lungs that were normal in appearance in all treated animals ( Fig. 3a) . In contrast, lungs from untreated animals were firm and edematous, failed to collapse ( Fig. 3a) and contained gross lesions with a mean affected area of 14.3% ( Fig. 3a and Supplementary Table 3) . Multifocal consolidation and dark red discoloration, consistent with interstitial pneumonia, was most prevalent on the dorsal surface of the lungs of untreated animals. We did not observe any other pathological changes at necropsy.
We used quantitative real-time RT-PCR (qRT-PCR) to determine viral loads as TCID 50 equivalents in tissues, fluids and nasal and throat swabs 19 . There was no detectable viral RNA in the blood at any time point or in urine taken at necropsy. Daily bronchial alveolar lavage samples showed similar viral loads between treated and untreated groups ( Supplementary Fig. 1 ). With the exception of the oronasopharynx 
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npg treated and untreated lung RLL samples; treated and untreated samples were also separated from naive control samples, indicating that treatment induces unique transcriptional changes. Using a relaxed P value cutoff (P < 0.05), we observed 966 differentially expressed genes (DEGs) when treated, infected and untreated, infected animals were compared to naive animals (Supplementary Table 4 ), many associated with innate antiviral processes induced by IFN-a2b and ribavirin 20, 21 . These included genes encoding type 1 and 3 IFN, pattern recognition receptors and IFN-induced with helicase C domain 1 (IFIH1, or MDA5), effector molecules and associated signal transducers. Comparison of uninfected, untreated animals to infected, treated and infected, untreated animals revealed lower expression of inflammatory genes in treated animals suggestive of milder disease (Supplementary Fig. 5 ). To elucidate the mechanism by which treatment reduces inflammation and disease during MERS-CoV infection, we sought to identify DEGs that are not associated with known IFN-stimulated gene induction programs. By examining the 205 DEGs identified using a more stringent P value cutoff (P < 0.01) (Fig. 4b and Supplementary Table 5) and Ingenuity Pathway Analysis, we identified many genes that were downregulated in untreated animals. Many of these were associated with hedgehog signaling (Fig. 4c) , a pathway involved in respiratory morphogenesis and vascularization [22] [23] [24] [25] [26] [27] and potentially involved in inflammatory injury 28 . In treated animals, we observed upregulation of sonic hedgehog (SHH) and subsequent downregulation of genes associated with cell proliferation (Supplementary Table 5) . SHH, the priming protein of the hedgehog pathway, and the associated molecule GLI family zinc finger 1 have been shown to block injurious responses in the pulmonary vasculature induced by multiple types of inflammatory and stress stimuli [29] [30] [31] [32] . Consistent with the reduced inflammation, reduction in cellular infiltrates and lack of perivasculitis in the lungs of treated animals, the upregulation of SHH suggests that the hedgehog pathway may regulate the host response to protect the lung from potentially injurious inflammation.
Rhesus macaques treated with IFN-a2b and ribavirin 8 h after MERS-CoV infection showed improved clinical parameters with no We monitored serum IFN-a levels to assess the delivery of IFNa2b. Treated animals had at least 2.3 times the level of IFN-a measured in untreated animals (1 and 3 d after infection), whereas 2 d after infection, treated animals had 37 times the level of untreated animals ( Supplementary Fig. 2) , which probably reflects the timing of IFN-a2b administration in relation to blood collection. Untreated animals showed evidence of an IFN response 1 and 2 d after infection, with means of 190 and 103 pg/ml, respectively; however, IFN-a was undetectable by 3 d after infection. Treated animals did not show alterations in systemic (serum) interleukin-2 (IL-2), monocyte chemotactic protein-1 (MCP-1), IL-1 receptor antagonist (IL-1RA), IL-6, IL-15 and IFN-g levels compared to those observed in untreated animals (Supplementary Fig. 3 ). We observed elevated local levels of IL-6, IFN-g and MCP-1 in homogenate from lung tissue collected 3 d after infection of untreated animals compared to treated animals (Supplementary Fig. 3 ), which indicates a tissue-specific host response to infection that is moderated by treatment.
We analyzed the effect of treatment on the lung transcriptome by microarray of RNA extracted from the right lower lobe (RLL). We performed a singular value decomposition-coupled multidimensional scaling (SVD-MDS) analysis, providing an overall view of the transcriptome, on samples from infected and uninfected animals in addition to control lung tissue samples from naive rhesus macaques (Fig. 4a) . breathing abnormalities and little evidence of pneumonia by X-ray. In addition, treated animals showed reduced systemic and local levels of proinflammatory markers. Lung tissues collected from treated animals 3 d after infection showed a significant reduction in viral genome copies, an absence of gross lesions and less severe histopathological changes compared to untreated animals. Microarray analysis of the lung supported the success of treatment and identified the hedgehog signaling pathway as a putative contributor to decreased lung damage. These data suggest that treatment of MERS-CoV-infected rhesus macaques with IFN-a2b and ribavirin improves outcome of infection. IFN-a2b and ribavirin treatment would be expected to provide the greatest benefit early in infection; however, the prolonged disease course in humans 8, 33 suggests that the treatment window may be considerably wider in the clinic. The disease severity in the rhesus macaque model, which seems most similar to mild to moderate human MERS-CoV cases, makes it difficult to extrapolate the outcome of this treatment in severe cases in humans. Thus, it is currently unknown whether initiation of treatment upon progression to severe respiratory illness would have any benefit, a situation faced in many acute infectious diseases. Additional therapeutics should be evaluated; however, given the severity and poor outcome of MERS-CoV infection, combined IFN-a2b and ribavirin therapy should be considered as an early intervention therapy for MERS-CoV.
Comparison of group means revealed a clear separation between the

METHODS
Methods and any associated references are available in the online version of the paper. Histopathology. Tissues were placed in cassettes and fixed in 10% neutral buffered formalin for 7 d. Subsequently, tissues were processed with a Sakura VIP-5 Tissue Tek, on a 12-h automated schedule, using a graded series of ethanol, xylene and ParaPlast Extra. Embedded tissues were sectioned at 5 µm and dried overnight at 42 °C before staining. Tissue sections were stained with H&E. Specific anti-CoV immunoreactivity was detected using a polyclonal rabbit antibody generated against hCoV-EMC/2012 at a 1:1,000 dilution. Tissues were also stained with a myeloperoxidase-specific antibody (1:450 dilution; 760-159, R&D Systems, Minneapolis, MN). The tissues were then processed for immunohistochemistry using the Discovery XT automated processor (Ventana Medical Systems) with a DAPMap (Ventana Medical Systems) kit, scanned with the Aperio ScanScope XT (Aperio Technologies, Inc.) and the entire section analyzed with the ImageScope Positive Pixel Count algorithm (version 9.1).
Genome quantification and microarray sample preparation. RNA from AVLtreated blood and RLT-treated tissues were extracted with the QiaAmp Viral RNA and the RNeasy kits, respectively (Qiagen). qRT-PCR using primers and probe previously described 19 were performed on the RotorGene Q (Qiagen). A tenfold dilution series of viral RNA based on TCID 50 equivalents was used as a standard. For microarray analysis, lung homogenates were stored at -80 °C in equal volumes RLT buffer (Qiagen) and 70% ethanol until preparation. Samples were thawed, and two additional volumes of RLT buffer with 0.01 volumes of 2-mercaptoethanol were added, followed by an additional two volumes of 70% ethanol. RNA was then extracted using RNeasy spin columns per the manufacturer's protocol. Low-yield samples were concentrated using the RNA Clean and Concentrator (Zymo Research). Probe labeling was carried out using the Agilent Low Input processing protocol, and probes were hybridized to Agilent Rhesus macaque 4×44K microarrays (Agilent Technologies) using the manufacturer's one-color analysis protocol.
Microarray data and functional analysis. For comparisons of differentially expressed genes (DEGs) in infected lungs of both IFN-a2b-and ribavirin-treated and untreated animals, raw array data were uploaded to Genedata Analyst 7.6 (Genedata). Data were normalized using the quantile normalization method, and the log 10 ratio expression was calculated relative to the mean probe values of the three untreated animals. Statistically significant DEGs were determined using Welch's t-test (P < 0.01, fold change ≥ 1.5). Hierarchical clustering of DEGs was performed by the unweighted average method (unweighted pair group with arithmetic mean; UPGMA) using Spotfire DecisionSite 9.1.1 (Tibco). Analysis of functional enrichment was performed using Ingenuity Pathway Analysis software (Ingenuity Systems). For measures of gene expression dynamics, the array data were normalized using NeONORM 36 and subjected to SVD-MDS analysis 37 . In parallel, the data for each individual were merged using weighted averages to generate combined profiles. These were visualized using SVD-MDS.
Statistical analyses.
With the exception of the data from the microarray experiment, data were analyzed in Prism (GraphPad Software) using the unpaired t-test, two-way ANOVA with Bonferroni's post hoc test and the Mann-Whitney test as indicated in the figure legends. 
